We compared functional imaging modalities including PET with 6-18 F-fluorodopamine ( 18 F-DA) with 123 I-metaiodobenzylguanidine ( 123 I-MIBG) and somatostatin receptor scintigraphy (SRS) with 111 In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age 6 SD, 44.2 6 14.2 y) with biochemically proven nonmetastatic (n 5 17) or metastatic (n 5 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: 18 F-DA PET, 123 I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis. Results: For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for 18 F-DA PET, 76.0% for 123 I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for 18 F-DA PET, 63.4% for 123 I-MIBG scintigraphy, and 64.0% for SRS. Conclusion: If available, 18 F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than 123 I-MIBG scintigraphy or SRS. If 18 F-DA PET is not available, 123 I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.
Unt il recently, the gold standard functional imaging method for pheochromocytoma (PHEO) was scintigraphy with 131 I-metaiodobenzylguanidine ( 131 I-MIBG), with sensitivity of 77%-90% and excellent specificity of 95%-100% (1) . However, it is scintigraphy with another radionuclide, 123 I-MIBG, that offers the option of performing SPECT and is reported to have sensitivity of 83%-100% and specificity of 95%-100% for detecting PHEO (2) (3) (4) . Scintigraphic imaging with 123 I-MIBG, compared with 131 I-MIBG, is advantageous because of its optimal g-emissions and lack of b-particles that result in a lower absorbed dose (5) . Availability of 123 I-MIBG, compared with 131 I-MIBG, is limited, but is expanding rapidly, especially in the United States. At present, large studies comparing various functional imaging modalities with 123 I-MIBG scintigraphy in the evaluation of PHEO are lacking.
PET also enables functional imaging of endocrine tumors. Although PET with 18 F-FDG has been used with some success for imaging metastatic PHEO, it is nevertheless a nonspecific ligand that shows uptake in various tumors (6) (7) (8) .
Other ligands, for example, 11 C-hydroxyephedrine and 11 Cepinephrine, have also been used successfully for PET imaging of PHEO (9) (10) (11) (12) . 18 F-labeled dihydroxyphenylalanine ( 18 F-DOPA) has enabled PET imaging of benign PHEOs and neck neuroendocrine tumors (13, 14) . Recently, we recommended the use of PET with 6-18 F-fluorodopamine ( 18 F-DA) for the detection of PHEO (15) (16) (17) . Our studies have suggested that 18 F-DA is a better agent than 131 I-MIBG for localization of metastatic PHEO (with 100% sensitivity vs. 56% sensitivity, respectively) (15, 16) . This is probably due to the better affinity of 18 F-DA than 131 I-MIBG for the norepinephrine membrane transport system and the increased resolution of PET, compared with planar g-camera imaging.
From in vitro and in vivo studies, it has been established that somatostatin receptor subtypes 3 and 4 are expressed in PHEO, including adrenal and metastatic disease (18) (19) (20) (21) . Although somatostatin receptor scintigraphy (SRS) with 111 In-pentetreotide (Octreoscan; Mallinckrodt Inc.) has only moderate affinity for these subtypes, compared with subtypes 2 and 5, SRS has been used with variable results to detect this tumor (18, (22) (23) (24) (25) . SRS reportedly detects neck paragangliomas with 94%-97% sensitivity (26) (27) (28) and has higher sensitivity for detecting metastatic PHEO than for detecting benign PHEO (29) . Nevertheless, in a small study of 10 patients with malignant PHEO and 3 patients with malignant paraganglioma that compared SRS with 131 I-or 123 I-MIBG scintigraphy, 26 lesions were MIBG-and SRS-positive, 15 lesions were MIBG-positive only, and 7 lesions were SRSpositive only (overall sensitivity for 131 I-and 123 I-MIBG scintigraphy was 85% and 92%, respectively, for SRS) (18) .
The aim of this study was to compare 18 F-DA PET, 123 I-MIBG, and SRS in the localization of adrenal, extraadrenal, and metastatic or multiple PHEOs in a large study from a single institution. We also evaluated which of these radiopharmaceuticals detected the largest number of lesions in patients with metastatic PHEO. Furthermore, we aimed to give physicians new information and recommendations for the use of various functional imaging methods when a nonmetastatic or metastatic PHEO is localized.
MATERIALS AND METHODS
All patients were enrolled in a study of PHEO approved by the National Institute of Child Health and Human Development Institutional Review Board, and written informed consent was obtained from all patients.
Subjects were retrospectively chosen from a larger group of 178 patients originally enrolled in a study of known or suspected PHEO. Specifically, inclusion criteria for this parent protocol included positive biochemistry, suggestive biochemistry with clinical signs or symptoms of catecholamine excess, and a family history of PHEO, with a tumor found on anatomic imaging studies even without clinical signs or symptoms. Exclusion criteria included inability to give informed consent and refusal or inability (e.g., claustrophobia, previous irradiation, or extreme obesity) to undergo examination, including many imaging studies. Children younger than 18 y and pregnant subjects were also excluded.
From this pool of 178 patients, 53 were retrospectively chosen for inclusion in this study on the basis of confirmed positive biochemical evidence of PHEO (using an in-house assay, as previously described (30, 31) ) and availability of certain imaging studies, including anatomic imaging (CT or MRI) and at least 2 of 3 of the following functional modalities: 18 F-DA PET, 123 I-MIBG scintigraphy, or SRS. The imaging studies had to be contemporaneously performed within 3 mo of each other.
CT scans of the neck, chest, abdomen, and pelvis were performed on a variety of equipment, including LightSpeed Ultra, LightSpeed QX/i, and HiSpeed CT/i scanners (GE Healthcare) and an Mx8000 IDT scanner (Philips). Section thickness was at the discretion of the radiologist and was set up to 3 mm in the neck, 5 mm in the chest and abdomen, and 7.5 mm in the pelvis, except for 2 cases in which scans of the neck were performed with either 3.75-or 5-mm images and another case in which chest, abdomen, and pelvis images were obtained with 10-mm thickness. All sections were contiguous. All studies were performed with a rapid infusion (130 mL injected at 2 mL/s) of nonionic water-soluble contrast agent.
MRI scans of the neck, chest, abdomen, and pelvis were obtained with 1.5-T Signa scanners (GE Healthcare), except for 1 study performed at an outside institution. Phased-array coils were used for neck imaging, and either phased-array torso or quadrature body coils were used elsewhere. T1-weighted gradient-echo and fatsuppressed, fast spin-echo T2-weighted imaging parameters were adjusted to minimize examination time and achieve desired anatomic coverage. Images were obtained in the axial plane, with additional planes when needed. All studies included a gadoliniumdiethylenetriaminepentaacetic acid contrast injection, using fatsuppressed T1-weighted gradient-echo imaging in the axial and coronal planes.
For 18 F-DA PET, the patients fasted overnight and were asked to avoid caffeine, tobacco, and alcohol for at least 12 h before the scan. 18 F-DA (37 MBq [1.0 mCi]) in 10 mL of normal saline was infused intravenously over 3 min. Attenuation-corrected images were obtained starting immediately after injection. 18 F-DA PET was performed using an Advance scanner (GE Healthcare) with a 15-cm field of view. The images were acquired in 2-dimensional mode from the base of the skull to the proximal thigh (in some patients in whom lesions were highly suspected in the head or the lower limbs, the PET studies also fully covered these areas). The emission scan lasted 8-15 min at each level. At least 1 transmission scan lasting 3-5 min was obtained at each level for attenuation correction.
For 123 I-MIBG, patients were imaged after intravenous administration of 123 I-MIBG (370 MBq [10.0 mCi]). Patients were instructed to take 100 mg of a saturated solution of potassium iodide by mouth twice a day for 4 d, starting the night before 123 I-MIBG administration. Medications known to interfere with 123 I-MIBG uptake were discontinued. Planar and SPECT images were acquired on a dual-head g-camera (ADAC Laboratories or Siemens Medical Solutions USA) and a triple-head g-camera (Trionix XLT; Trionix Laboratories), respectively, equipped with low-energy highresolution collimators. A total of 120 sequential (40 stops per head) 40-s images were obtained. The images were reconstructed with the manufacturer's software using a standard filtered backprojection algorithm. A Butterworth filter was used for reconstruction. Twenty-four hours after injection, whole-body and SPECT scans of the head through the pelvis were performed. SPECT studies were repeated at 48 h as needed.
For SRS, patients were imaged approximately 4 and 24 h after intravenous administration of 111 In-pentetreotide (222 MBq [6 mCi]). Whole-body and SPECT scans of the head through the pelvis were acquired on a dual-head g-camera (ADAC Laboratories or Siemens Medical Solutions USA) and a triple-head g-camera (Trionix XLT; Trionix Laboratories), respectively, equipped with medium-energy general-purpose collimators. On occasion, 48-h SPECT images were also obtained. A total of 120 sequential 40-s images were obtained. The images were reconstructed with the manufacturer's software using a standard filtered backprojection algorithm. A Hamming filter was used for reconstruction.
The radiologist who interpreted the CT and MRI findings was unaware of the results of 18 F-DA PET, 123 I-MIBG scintigraphy, and SRS. Moreover, nuclear medicine studies were read independently of each other and of the anatomic studies by 2 physicians. Sites of uptake outside the normal distribution were considered abnormal. 123 I-MIBG uptake in the adrenal glands was considered normal if it was mild, symmetric, and not enlarged. However, any visualized uptake of 18 F-DA in the adrenals was considered to be abnormal, on the basis of previous experience with studies in a small number of healthy volunteers who did not show any adrenal 18 F-DA uptake. Abnormal foci seen in nuclear medicine studies were graded on a scale of 1-5 (1, not PHEO; 2, probably not PHEO; 3, equivocal; 4, probably PHEO; and 5, definitely PHEO). Only lesions with scores of 4 and 5 were counted as positive findings. Discrepancies in scans from the first individual masked reading were resolved by a joint meeting of both nuclear medicine physicians in a consensus review (with reexamination and discussion of the studies in question).
Comparison of the results of the nuclear medicine modalities was done on a per-patient and a per-region basis. For the former, scans were considered positive if at least 1 lesion with a score of 4 of 5 or 5 of 5 was seen, regardless of the number of foci (scans with no or equivocal uptake were scored as negative). Because histologic proof of metastatic lesions was largely unavailable, findings on CTor MRI were taken as our reference standard (despite shortcomings of these modalities, as described in the ''Discussion'' section) for sensitivity calculations of imaging studies. Sensitivity by patient was calculated as follows: the number of patients positive on 18 F-DA PET, 123 I-MIBG scintigraphy, or SRS divided by the number of patients positive on CT/MRI.
Analysis on a per-region basis was performed over the following areas: left adrenal gland, right adrenal gland, liver, abdominal/pelvic compartment (excluding adrenal glands and liver), lungs, mediastinum, neck, and bone (including skull). For sensitivity calculations, studies were considered either positive or negative, regardless of the number of lesions detected in each region. CT or MRI findings were considered to be the reference standard. Sensitivity by region was calculated as follows: the number of regions positive on 18 F-DA PET, 123 I-MIBG scintigraphy, or SRS divided by the number of regions positive on CT/MRI. Only regions that were actually covered by 18 F-DA PET, 123 I-MIBG scintigraphy, or SRS and by either CT or MRI were included.
The McNemar test was used to compare sensitivities between different imaging modalities. A 2-sided P value less than 0.05 was considered significant.
RESULTS
Imaging results from 25 men and 28 women (mean age 6 SD, 44.2 6 14.2 y) with biochemically proven nonmetastatic (n 5 17, 2 patients with recurrent disease: 10 patients had T1 N0 M0 disease, stage I; 3 patients had T2 N0 M0 disease, Anatomic imaging was positive in all patients. Most lesions seen on CT/MRI showed uptake with at least 1 functional imaging modality. In a few patients, because the enormous number of metastatic lesions did not permit direct one-to-one comparisons, comparisons on a per-patient and a per-region basis were made. In patients with nonmetastatic PHEO, negative functional imaging studies were obtained in 2 patients with 18 F-DA PET, 2 patients with 123 I-MIBG scintigraphy, and 5 patients with SRS. The following provides more detail, because evaluation on a per-lesion basis was feasible only in these patients with nonmetastatic PHEO: 16 lesions positive on CT/MRI were missed by either 18 F-DA PET or 123 I-MIBG (in 16 patients), whereas 13 lesions positive on CT/MRI were missed by SRS (in 7 patients). In patients with metastatic PHEO, negative functional imaging studies were obtained in 4 patients with 18 F-DA PET, 9 patients with 123 I-MIBG scintigraphy, and 1 patient with SRS.
For this available cohort, on a per-patient basis, sensitivity was equal for 18 F-DA PET and 123 I-MIBG scintigraphy (87.5%) and lower for SRS (28.5%) in patients with nonmetastatic PHEO (Table 1 ). In patients with metastatic PHEO, sensitivity was 91.4% for 18 F-DA PET, 70.6% for 123 I-MIBG, and 88.9% for SRS (Table 1) . Overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for 18 F-DA PET, 76.0% for 123 I-MIBG, and 22.0% for SRS. Furthermore, on a per-region basis, sensitivity was 67% for 18 F-DA PET, 75% for 123 I-MIBG, and 37.5% for SRS in patients with nonmetastatic PHEO (Table 2 ). In patients with metastatic PHEO, In several patients, functional imaging modalities showed lesions in regions that were negative on CTor MRI. With 18 F-DA PET, compared with CT or MRI, lesions were shown in 5 more patient regions in 5 patients (in the adrenals or the abdominal or pelvic compartment), and with 123 I-MIBG scintigraphy, 1 additional positive region in 1 patient (in the right adrenal) was seen.
In patients with nonmetastatic PHEO who were studied with all 3 functional imaging modalities, 18 F-DA PET and 123 I-MIBG scintigraphy were more positive on a per-patient and on a per-region basis than was SRS (Table 3 ; Fig. 1 ). In patients with metastatic PHEO who were studied with all 3 functional imaging modalities, 18 F-DA PET and SRS were more positive on a per-patient basis than was 123 I-MIBG scintigraphy, whereas on a per-region basis, SRS was more positive than were 18 F-DA PET and 123 I-MIBG scintigraphy (Table 3 ; Fig. 2 ).
DISCUSSION
In this largest-to-date comparison study of 18 F-DA PET with 123 I-MIBG scintigraphy and SRS in 17 patients with nonmetastatic PHEO and 36 patients with metastatic PHEO, overall more foci of uptake were shown with 18 F-DA PET than with the other functional imaging modalities. In nonmetastatic PHEO, 18 F-DA PET imaged slightly fewer foci than did 123 I-MIBG scintigraphy (and both detected more foci than did SRS), but in metastatic PHEO, 18 F-DA PET detected more foci than did 123 I-MIBG scintigraphy and SRS. Some, mainly metastatic, lesions were localized by 1 modality only, but no distinct pattern for any particular tumor size or Regions included left adrenal gland, right adrenal gland, liver, abdominal/pelvic compartment (excluding adrenal glands and liver), lungs, mediastinum, neck, and bone (including head or skull). region emerged. Overall, the scintigraphic modality with the highest sensitivity for localizing PHEO was 18 F-DA PET (75.4%), followed by 123 I-MIBG (63.4%) and SRS (64%).
In many patients with PHEO (especially in those with extraadrenal PHEO, adrenal PHEO larger than 5 cm, or mutations of genes encoding mainly subunits B and D of the mitochondrial enzyme succinate dehydrogenase [SDHB and SDHD]), the possibility of metastatic disease or multiple tumors should be considered (or excluded). For this, functional imaging modalities are most useful (3, 6, 9, 16, 17, (32) (33) (34) . The sensitivity of CT and MRI for detecting extraadrenal or metastatic PHEO is approximately 90% (or lower, when postoperative changes prevent the correct localization of tumors) (35) (36) (37) (38) (39) . Moreover, the specificities of both CT and MRI scans are disappointingly low (as low as 60%) in localizing PHEO (particularly metastatic PHEO) (3). In this study, both CT and MRI also missed lesions that were detected by functional imaging studies. Although we do not have surgical confirmation that the lesions seen on functional imaging and not on anatomic imaging were PHEO, we were confident that most of them were real based on clinical follow-up, including improvement after chemotherapy or 131 I-MIBG therapy in many cases.
PET is a physiologic method of imaging that depends on selective binding or uptake and retention of radiolabeled agents by different tissues. It has the advantages of rapid imaging and high spatial and temporal resolution. Several PET agents have been used for localizing PHEO, including 18 F-FDG (6,12,40), 11 C-hydroxyephedrine (10,12,41), 11 Cepinephrine (11), 18 F-DA (15, 16) , and 18 F-DOPA (13, 14) . A comparison study of 131 I-and 123 I-MIBG and 18 F-FDG PET scans in patients with malignant PHEO showed that 18 F-FDG PET was superior to MIBG (6) . Furthermore, 18 F-FDG PET was recently shown to be superior to 18 F-DA or 123 I-MIBG in localizing metastases of highly malignant paragangliomas (in particular those with SHDB mutations) (7). However, 18 F-FDG remains nonspecific for PHEO, as 18 F-FDG also detects many other types of tumors. PET with 11 C-hydroxyephedrine and 11 C-epinephrine has yielded better results than has PET with 18 F-FDG for the diagnostic localization of PHEO, although the short physical half-lives (t 1/2 5 20 min) of these radiopharmaceuticals will likely preclude their more widespread use (10, 12, 41) . Recently, PET with 18 F-DOPA, a labeled precursor of dopamine, was used in a study of 14 patients with benign adrenal PHEO and a small number of patients (n 5 3) with extraadrenal nonmetastatic PHEO (14) . In the former group, all tumors were localized with 18 F-DOPA PET, whereas in the latter group, 18 F-DOPA PET was concordant with MRI results in 1 of 3 patients and imaged a tumor that was not seen with 131 I-MIBG scintigraphy (14) . In another study of 10 patients with glomus jugulare tumors (which arise from the paraganglionic tissue of the head and neck and are similar to PHEOs), 11 of the 15 presumed tumors diagnosed by 18 F-DOPA PET were confirmed by MRI (13) .
At the National Institutes of Health, we have used 18 F-DA with excellent results in localizing both adrenal and extraadrenal PHEOs, including metastatic lesions (15, 16, 42, 43) . In a previous study of patients with metastatic PHEO, we found that 18 F-DA PET was clearly superior to 131 I-MIBG (with sensitivities of 100% and 56%, respectively) (16) . The availability of 123 I-MIBG prompted us to compare it with 18 F-DA PET as well. In the present study, in patients with nonmetastatic (mainly adrenal) PHEOs, 18 F-DA and 123 I-MIBG had equivalent sensitivities for tumor detection, and both were superior to SRS. In patients with metastatic disease, 18 F-DA was superior to 123 I-MIBG and detected more lesions. In a minority of these patients, SRS showed impressively more lesions than did 123 I-MIBG. Additional advantages of PET, compared with other functional imaging modalities, include the means of immediate whole-body imaging, the possibility of quantitative assessment of uptake, and the absence of artifacts from scar tissue or from the presence of metallic clips after surgery (44) . In fact, 18 F-DA scan artifacts appear to be quite rare, and in this study no artifacts were noted except for mild adrenal uptake in some patients, which was scored as abnormal (although we have since found that this can be normal). Known artifacts with 18 F-DA scans also include uptake in adrenal hyperplasia and metabolically active brown fat.
In PHEO, 131 I-MIBG offers high specificity (95%-100%) with lower sensitivity (56%-77%) (43, 45) . Sensitivity is elevated to 78%-91%, and specificity is preserved (3, 46, 47) using 123 I-MIBG. In the present study, 123 I-MIBG was as sensitive as 18 F-DA and definitely superior to SRS in localizing nonmetastatic PHEO. However, in the evaluation of metastatic PHEO, 123 I-MIBG was the least informative scintigraphic modality, lagging behind 18 F-DA and SRS.
SRS is used effectively for the diagnostic localization of neuroendocrine tumors (48, 49) . In a small number of reports comparing the diagnostic accuracy of SRS with 123 I-or 131 I-MIBG in patients with metastatic PHEO, SRS had an overall higher detection rate: SRS found up to 87% of lesions, whereas 123 I-MIBG localized only 57% (4, 18, 24, 25, 29) . SRS studies may be particularly useful as a functional imaging modality in patients with rapidly progressing and growing PHEOs. In these PHEOs, changes in genetic and cellular characteristics occur, currently by unknown mechanisms such as the expression of somatostatin receptors. In this study, SRS failed to detect the 5 of 7 tumors in patients with nonmetastatic disease. However, in metastatic PHEO, although 18 F-DA localized many lesions that SRS did not, SRS also showed a substantial number of metastatic lesions that were not detected with 18 F-DA. In addition, SRS showed more lesions than did 123 I-MIBG in patients with metastatic disease ( 123 I-MIBG provided the least additional information in these patients). Clinically, patients with predominantly SRS-positive lesions had rapidly progressing tumors on the basis of our clinical follow-up, repeated biochemistry, and anatomic imaging studies.
This report has shortcomings that should be mentioned. First, only 1 patient with extraadrenal nonmetastatic PHEO was studied, and future studies are needed to address this subset of patients. Second, only 5 patients with nonmetastatic PHEO were studied with all 3 functional imaging modalities, a deficiency that needs to be addressed as well. Third, most patients with metastatic PHEO did not undergo surgery, as it could not be justified clinically, and therefore, surgical confirmation of disease is not available for most lesions in these patients. Fourth, fewer SRS studies than 18 F-DA and 123 I-MIBG studies were performed; with such unequal size groups, selection bias toward performing SRS studies in patients with metastatic disease may have occurred. Fifth, we considered 18 F-DA uptake in the adrenals as being abnormal. However, with further experience and the use of PET/CT, we have since found that healthy adrenal glands in some patients may demonstrate mild adrenal uptake of 18 F-DA (lean body mass, maximum standardized uptake value , 7.3) (50). Finally, ascertainment bias (i.e., the tendency to produce false results and conclusions based on a distorted or nontypical sample) may have occurred, principally due to the rareness of the tumors that were studied. Nevertheless, despite negative MIBG scans before referral in 1 patient with nonmetastatic and 4 with metastatic PHEOs, all the study subjects had biochemical proof of disease.
CONCLUSION
In the diagnostic evaluation of PHEO, 18 F-DA PET and 123 I-MIBG are more sensitive than SRS in detecting nonmetastatic primary adrenal PHEO. For metastatic PHEO, 18 F-DA is more sensitive than SRS, and both are superior to 123 I-MIBG. In patients with rapidly progressing and growing PHEOs, SRS may detect lesions that are negative on both 18 F-DA and 123 I-MIBG scans. In a study of patients with familial-SDHB-associated disease, PET with 18 F-FDG was shown to be the superior functional imaging method. In those patients with PHEO in whom anatomic imaging modalities indicate adrenal disease, 123 I-MIBG is a valuable imaging modality to be used; this modality is comparable with other specific imaging methods such as 18 F-DA PET. For those with metastatic disease, SRS can be used. However, this approach should not exclude 18 F-DA PET, which is as sensitive as 123 I-MIBG and SRS for detecting nonmetastatic and metastatic PHEO, respectively. As PET becomes more available, either 18 F-DA PET or PET with another specific PET ligand will become the method of choice for functional imaging of nonmetastatic and metastatic PHEO.
